# Hemoglobin Based Oxygen Therapeutics in Elective Percutaneous Coronary Revascularization

> **NCT00479895** · PHASE2 · COMPLETED · sponsor: **Biopure Corporation** · enrollment: 5 (actual)

## Conditions studied

- Coronary Occlusion
- Acute Coronary Syndrome

## Interventions

- **DRUG:** Hemoglobin Based Oxygen Carrier-201 (HBOC-201, Hemopure)

## Key facts

- **NCT ID:** NCT00479895
- **Lead sponsor:** Biopure Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2008-03
- **Final completion:** 2008-04
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2008-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00479895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00479895, "Hemoglobin Based Oxygen Therapeutics in Elective Percutaneous Coronary Revascularization". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00479895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*